Natural clay mineral dietary supplements delivering calcium, magnesium, potassium, and sodium in ion-exchange form

Overview

This solution offers food additives and dietary supplements based on natural porous and layered aluminosilicate clay minerals. The products contain calcium, magnesium, potassium, and sodium in ion-exchange form within the mineral structure. When ingested, the minerals release these essential microelements into the gastrointestinal tract for absorption by the body.

The core value proposition addresses a well-documented nutritional challenge: calcium requires magnesium to properly form bone tissue and avoid calcification of soft tissues such as the myocardium and thyroid gland. Magnesium in turn requires potassium to enter cells through protein pathways, and sodium is needed to maintain the potassium-sodium pump that supports cellular function. The supplements deliver all four minerals simultaneously in a bioavailable form, which the proposer claims distinguishes them from existing single-mineral or limited-combination products on the market.

The products have been sold through pharmacy chains in Ukraine for 15 years and have been recommended by physicians for oral administration to patients during that period. The proposer is seeking partnership to relocate production outside Ukraine due to the ongoing conflict.

Technical specifications

• Mineral source: Natural porous and layered alumosilicate clay minerals containing calcium, magnesium, sodium, and potassium in ion-exchange form
• Delivery mechanism: Ion-exchange release of microelements in the gastrointestinal tract
• Claimed effectiveness: 100% effectiveness with no reported side effects over 15 years of use
• Target population: Pregnant women and patients requiring mineral supplementation
• Distribution history: Sold through pharmacy chains in Ukraine for 15 years with physician recommendations
• Form: Food additives and dietary supplements for oral administration

Technology readiness level

The products have been commercially available through Ukrainian pharmacy chains for 15 years with physician endorsements. However, formal pharmaceutical validation has not yet been completed. Future validation requires in vitro and in vivo studies, estimated to take approximately 2 years if conducted in parallel, to support release of a pharmaceutical-grade product. The proposer is actively seeking partnership to relocate manufacturing operations to another country.